The U.S. District Court for the Northern District of Mississippi has entered a consent decree prohibiting Delta Pharma from manufacturing or distributing compounded drugs until they comply with the Federal Food, Drug, and Cosmetic Act and FDA regulations, the Food and Drug Administration announced Friday. The company is registered as an outsourcing facility under Section 503B of the Act. "That legislation envisioned an important role for outsourcing facilities to help supply providers with compounded medicines, but it also required that these firms meet good manufacturing practice requirements,” said FDA Commissioner Scott Gottlieb, M.D. “When we find outsourcing facilities that continue to violate the law by not adhering to these manufacturing requirements, and put patients at risk, we’re going to hold them accountable under the law. At the same time, we’re also pursuing new policy steps to help make it more feasible for compounders to meet the requirements of becoming an outsourcing facility.”

Related News Articles

Headline
The House Energy and Commerce Committee held a markup April 29 where it advanced the AHA-supported SUPPORT Act (H.R. 2483). The legislation would reauthorize…
Perspective
Public
Congressional lawmakers are heading home for a two-week district work period after both the Senate and House passed a revised budget resolution for fiscal year…
Headline
The Government Accountability Office yesterday released a report calling for the Department of Health and Human Services to improve its efforts responding to…
Headline
Story Updated April 5 at 8:30 a.m. ETThe Senate by a vote of 51 to 48 passed its revised budget resolution for fiscal year 2025 with Sens. Rand…
Headline
The AHA and dozens of other organizations yesterday urged House and Senate sponsors of the Conrad State 30 and Physician Access Reauthorization Act to…
Headline
The AHA March 27 voiced opposition to the Physician Led and Rural Access to Quality Care Act (H.R. 2191), a bill that would lift the ban on the establishment…